Description

TELVAS-AM 80/5MG (1X15)

Indications

TELVAS-AM 80/5MG is a combination medication primarily indicated for the management of hypertension (high blood pressure) and for the treatment of heart failure. This formulation contains Telmisartan and Amlodipine, which work synergistically to lower blood pressure and improve cardiovascular outcomes. It is typically prescribed for patients who require multiple antihypertensive agents to achieve optimal blood pressure control.

Mechanism of Action

The active components of TELVAS-AM, Telmisartan and Amlodipine, have distinct mechanisms of action. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to its receptor, leading to vasodilation and a reduction in blood pressure. By blocking this receptor, Telmisartan decreases the secretion of aldosterone, resulting in decreased sodium and water retention.

Amlodipine, on the other hand, is a long-acting dihydropyridine calcium channel blocker. It inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to relaxation of the vascular smooth muscle, reduced peripheral vascular resistance, and ultimately lowering blood pressure. The combination of these two drugs enhances antihypertensive efficacy and provides additional benefits in patients with coexisting conditions such as coronary artery disease.

Pharmacological Properties

TELVAS-AM exhibits a pharmacokinetic profile characterized by good oral bioavailability. Telmisartan is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 hour. It has a half-life of approximately 24 hours, allowing for once-daily dosing. Amlodipine also has a long half-life, around 30 to 50 hours, which contributes to sustained antihypertensive effects over a 24-hour period.

The combination of these two agents allows for effective blood pressure control throughout the day, minimizing fluctuations in blood pressure and reducing the risk of cardiovascular events. The pharmacodynamics of TELVAS-AM demonstrate a significant reduction in both systolic and diastolic blood pressure in clinical studies, making it a valuable option for hypertensive patients.

Contraindications

TELVAS-AM is contraindicated in patients with known hypersensitivity to Telmisartan, Amlodipine, or any of the excipients in the formulation. It should not be used in patients with severe hypotension, cardiogenic shock, or aortic stenosis. Additionally, the medication is contraindicated in patients with renal artery stenosis, as it may lead to renal impairment. Pregnant and breastfeeding women should avoid this medication due to potential risks to the fetus or infant.

Side Effects

The use of TELVAS-AM may be associated with several side effects, although not all patients will experience them. Common side effects include dizziness, headache, fatigue, and peripheral edema. Less common but more serious side effects may include hypotension, elevated liver enzymes, and renal impairment. Patients should be monitored for signs of these adverse effects, especially during the initiation of therapy or dosage adjustments.

In rare cases, allergic reactions such as angioedema may occur. If any signs of severe allergic reactions appear, such as difficulty breathing or swelling of the face, lips, or throat, immediate medical attention should be sought.

Dosage and Administration

The recommended starting dose of TELVAS-AM is typically 80/5 mg once daily. Depending on the patient’s response and blood pressure levels, the dosage may be adjusted. The maximum recommended dose is 80/10 mg once daily. It is important for patients to take the medication at the same time each day to maintain consistent blood levels and maximize therapeutic effects.

Patients should be advised to swallow the tablets whole with water and not to chew or crush them. It is also recommended to monitor blood pressure regularly to assess the effectiveness of the treatment and make necessary adjustments.

Interactions

TELVAS-AM may interact with other medications, which could affect its efficacy or increase the risk of side effects. Notable interactions include non-steroidal anti-inflammatory drugs (NSAIDs), which may reduce the antihypertensive effect of Telmisartan. Caution should be exercised when combining TELVAS-AM with other antihypertensive agents, as additive effects may lead to hypotension.

Additionally, patients taking potassium supplements or potassium-sparing diuretics should be monitored closely, as the combination may lead to hyperkalemia. Grapefruit juice may also affect the metabolism of Amlodipine, potentially increasing its concentration and risk of side effects. It is essential for patients to inform their healthcare provider of all medications they are taking to manage potential interactions effectively.

Precautions

Before initiating treatment with TELVAS-AM, healthcare providers should conduct a thorough assessment of the patient’s medical history, including any history of renal impairment, liver disease, or heart failure. Regular monitoring of renal function and electrolytes is recommended, especially in patients with pre-existing conditions.

Patients should be counseled about the potential for dizziness or lightheadedness, particularly after the first dose or when increasing the dose. It is advisable to avoid activities that require mental alertness until they know how the medication affects them. Additionally, patients should be advised to maintain adequate hydration and to report any unusual symptoms or side effects to their healthcare provider promptly.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of TELVAS-AM in managing hypertension. In a randomized controlled trial, patients receiving TELVAS-AM showed significant reductions in both systolic and diastolic blood pressure compared to those receiving placebo. The combination therapy was well-tolerated, with a low incidence of adverse effects reported.

Another study highlighted the benefits of TELVAS-AM in patients with comorbid conditions, such as diabetes and coronary artery disease. The results indicated that the combination therapy not only effectively controlled blood pressure but also improved overall cardiovascular outcomes, reducing the risk of major adverse cardiovascular events.

Conclusion

TELVAS-AM 80/5MG is a valuable therapeutic option for patients with hypertension and related cardiovascular conditions. The combination of Telmisartan and Amlodipine provides effective blood pressure control while minimizing the risk of adverse effects. As with any medication, it is crucial for patients to use TELVAS-AM responsibly and under the guidance of a healthcare professional to achieve optimal health outcomes.